Combined therapy with desferrioxamine and deferiprone in beta thalassemia major patients with transfusional iron overload

S. Daar, A. V. Pathare

Research output: Contribution to journalArticle

63 Citations (Scopus)

Abstract

Iron overload is the main cause of morbidity and mortality especially from heart failure in patients with beta thalassemia major (TM). Successful iron chelation is therefore essential for the optimal management of TM. Although desferrioxamine (DFX) has been the major iron-chelating treatment of transfusional iron overload, compliance is a major hindrance in achieving optimal therapeutic results. The availability of oral iron chelation with deferiprone (L1) since 1987 is useful but showed poor efficacy when used alone as compared to DFX. We therefore decided to compare DFX alone with a prospective combined therapy with DFX and L1 in beta thalassemia major patients with iron overload. We studied 91 patients with beta thalassemia major (mean age±SD, 15.02±5.8; range 2-30 years) attending the day care unit for regular transfusional support. They received packed red cells every 3-4 weeks to maintain pretransfusion hemoglobin concentration above 9 g/dl. They had been receiving DFX at a daily dose of 40 mg kg-1 day-1 by subcutaneous infusion for 8-10 h on 4-5 nights each week for the past several years. However, due to various reasons, they had developed considerable transfusional iron overload. These patients were allocated to prospectively receive additional therapy with oral iron chelator L1 at 75 mg kg-1 day-1 body weight in three divided doses with food after informed consent and continued to receive treatment with DFX as per the above dosage. Of the 91 patients, six developed severe gastrointestinal (GI) upset, two agranulocytosis, two arthropathy, one persistently raised liver enzymes, two died owing to sepsis, and two received allogeneic bone marrow transplantation. Amongst the remaining 76 patients, 21 were found noncompliant (not taking DFX regularly, but taking L1 regularly). Thus, in the 55 evaluable patients {6-48 months on combination therapy; mean [(±SD)22±12 months]}, the mean serum ferritin (±SD) fell dramatically from 3,088 (±1,299) ng/ml (DFX alone) to 2,051 (±935) ng/ml (DFX and L1; p1. Our results also demonstrate a significant statistical improvement after as little as 6 months of combination therapy. Furthermore, these improvements lead to a progressive fall in the mean serum ferritin. Lastly, the study also demonstrates significant improvement in the echocardiographic parameters of myocardial performance in these patients receiving combination therapy.

Original languageEnglish
Pages (from-to)315-319
Number of pages5
JournalAnnals of Hematology
Volume85
Issue number5
DOIs
Publication statusPublished - May 2006

Fingerprint

Deferoxamine
Iron Overload
beta-Thalassemia
Iron
Therapeutics
Ferritins
deferiprone
Subcutaneous Infusions
Agranulocytosis
Joint Diseases
Homologous Transplantation
Chelating Agents
Informed Consent
Serum
Bone Marrow Transplantation
Compliance
Sepsis
Hemoglobins
Heart Failure
Body Weight

Keywords

  • Beta thalassemia major
  • Deferiprone(L)
  • Desferrioxamine(DFX)
  • Transfusional iron overload

ASJC Scopus subject areas

  • Hematology

Cite this

Combined therapy with desferrioxamine and deferiprone in beta thalassemia major patients with transfusional iron overload. / Daar, S.; Pathare, A. V.

In: Annals of Hematology, Vol. 85, No. 5, 05.2006, p. 315-319.

Research output: Contribution to journalArticle

@article{3e32b8ef30a94842a95502610e88fb50,
title = "Combined therapy with desferrioxamine and deferiprone in beta thalassemia major patients with transfusional iron overload",
abstract = "Iron overload is the main cause of morbidity and mortality especially from heart failure in patients with beta thalassemia major (TM). Successful iron chelation is therefore essential for the optimal management of TM. Although desferrioxamine (DFX) has been the major iron-chelating treatment of transfusional iron overload, compliance is a major hindrance in achieving optimal therapeutic results. The availability of oral iron chelation with deferiprone (L1) since 1987 is useful but showed poor efficacy when used alone as compared to DFX. We therefore decided to compare DFX alone with a prospective combined therapy with DFX and L1 in beta thalassemia major patients with iron overload. We studied 91 patients with beta thalassemia major (mean age±SD, 15.02±5.8; range 2-30 years) attending the day care unit for regular transfusional support. They received packed red cells every 3-4 weeks to maintain pretransfusion hemoglobin concentration above 9 g/dl. They had been receiving DFX at a daily dose of 40 mg kg-1 day-1 by subcutaneous infusion for 8-10 h on 4-5 nights each week for the past several years. However, due to various reasons, they had developed considerable transfusional iron overload. These patients were allocated to prospectively receive additional therapy with oral iron chelator L1 at 75 mg kg-1 day-1 body weight in three divided doses with food after informed consent and continued to receive treatment with DFX as per the above dosage. Of the 91 patients, six developed severe gastrointestinal (GI) upset, two agranulocytosis, two arthropathy, one persistently raised liver enzymes, two died owing to sepsis, and two received allogeneic bone marrow transplantation. Amongst the remaining 76 patients, 21 were found noncompliant (not taking DFX regularly, but taking L1 regularly). Thus, in the 55 evaluable patients {6-48 months on combination therapy; mean [(±SD)22±12 months]}, the mean serum ferritin (±SD) fell dramatically from 3,088 (±1,299) ng/ml (DFX alone) to 2,051 (±935) ng/ml (DFX and L1; p1. Our results also demonstrate a significant statistical improvement after as little as 6 months of combination therapy. Furthermore, these improvements lead to a progressive fall in the mean serum ferritin. Lastly, the study also demonstrates significant improvement in the echocardiographic parameters of myocardial performance in these patients receiving combination therapy.",
keywords = "Beta thalassemia major, Deferiprone(L), Desferrioxamine(DFX), Transfusional iron overload",
author = "S. Daar and Pathare, {A. V.}",
year = "2006",
month = "5",
doi = "10.1007/s00277-005-0075-z",
language = "English",
volume = "85",
pages = "315--319",
journal = "Annals of Hematology",
issn = "0939-5555",
publisher = "Springer Verlag",
number = "5",

}

TY - JOUR

T1 - Combined therapy with desferrioxamine and deferiprone in beta thalassemia major patients with transfusional iron overload

AU - Daar, S.

AU - Pathare, A. V.

PY - 2006/5

Y1 - 2006/5

N2 - Iron overload is the main cause of morbidity and mortality especially from heart failure in patients with beta thalassemia major (TM). Successful iron chelation is therefore essential for the optimal management of TM. Although desferrioxamine (DFX) has been the major iron-chelating treatment of transfusional iron overload, compliance is a major hindrance in achieving optimal therapeutic results. The availability of oral iron chelation with deferiprone (L1) since 1987 is useful but showed poor efficacy when used alone as compared to DFX. We therefore decided to compare DFX alone with a prospective combined therapy with DFX and L1 in beta thalassemia major patients with iron overload. We studied 91 patients with beta thalassemia major (mean age±SD, 15.02±5.8; range 2-30 years) attending the day care unit for regular transfusional support. They received packed red cells every 3-4 weeks to maintain pretransfusion hemoglobin concentration above 9 g/dl. They had been receiving DFX at a daily dose of 40 mg kg-1 day-1 by subcutaneous infusion for 8-10 h on 4-5 nights each week for the past several years. However, due to various reasons, they had developed considerable transfusional iron overload. These patients were allocated to prospectively receive additional therapy with oral iron chelator L1 at 75 mg kg-1 day-1 body weight in three divided doses with food after informed consent and continued to receive treatment with DFX as per the above dosage. Of the 91 patients, six developed severe gastrointestinal (GI) upset, two agranulocytosis, two arthropathy, one persistently raised liver enzymes, two died owing to sepsis, and two received allogeneic bone marrow transplantation. Amongst the remaining 76 patients, 21 were found noncompliant (not taking DFX regularly, but taking L1 regularly). Thus, in the 55 evaluable patients {6-48 months on combination therapy; mean [(±SD)22±12 months]}, the mean serum ferritin (±SD) fell dramatically from 3,088 (±1,299) ng/ml (DFX alone) to 2,051 (±935) ng/ml (DFX and L1; p1. Our results also demonstrate a significant statistical improvement after as little as 6 months of combination therapy. Furthermore, these improvements lead to a progressive fall in the mean serum ferritin. Lastly, the study also demonstrates significant improvement in the echocardiographic parameters of myocardial performance in these patients receiving combination therapy.

AB - Iron overload is the main cause of morbidity and mortality especially from heart failure in patients with beta thalassemia major (TM). Successful iron chelation is therefore essential for the optimal management of TM. Although desferrioxamine (DFX) has been the major iron-chelating treatment of transfusional iron overload, compliance is a major hindrance in achieving optimal therapeutic results. The availability of oral iron chelation with deferiprone (L1) since 1987 is useful but showed poor efficacy when used alone as compared to DFX. We therefore decided to compare DFX alone with a prospective combined therapy with DFX and L1 in beta thalassemia major patients with iron overload. We studied 91 patients with beta thalassemia major (mean age±SD, 15.02±5.8; range 2-30 years) attending the day care unit for regular transfusional support. They received packed red cells every 3-4 weeks to maintain pretransfusion hemoglobin concentration above 9 g/dl. They had been receiving DFX at a daily dose of 40 mg kg-1 day-1 by subcutaneous infusion for 8-10 h on 4-5 nights each week for the past several years. However, due to various reasons, they had developed considerable transfusional iron overload. These patients were allocated to prospectively receive additional therapy with oral iron chelator L1 at 75 mg kg-1 day-1 body weight in three divided doses with food after informed consent and continued to receive treatment with DFX as per the above dosage. Of the 91 patients, six developed severe gastrointestinal (GI) upset, two agranulocytosis, two arthropathy, one persistently raised liver enzymes, two died owing to sepsis, and two received allogeneic bone marrow transplantation. Amongst the remaining 76 patients, 21 were found noncompliant (not taking DFX regularly, but taking L1 regularly). Thus, in the 55 evaluable patients {6-48 months on combination therapy; mean [(±SD)22±12 months]}, the mean serum ferritin (±SD) fell dramatically from 3,088 (±1,299) ng/ml (DFX alone) to 2,051 (±935) ng/ml (DFX and L1; p1. Our results also demonstrate a significant statistical improvement after as little as 6 months of combination therapy. Furthermore, these improvements lead to a progressive fall in the mean serum ferritin. Lastly, the study also demonstrates significant improvement in the echocardiographic parameters of myocardial performance in these patients receiving combination therapy.

KW - Beta thalassemia major

KW - Deferiprone(L)

KW - Desferrioxamine(DFX)

KW - Transfusional iron overload

UR - http://www.scopus.com/inward/record.url?scp=33646677440&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646677440&partnerID=8YFLogxK

U2 - 10.1007/s00277-005-0075-z

DO - 10.1007/s00277-005-0075-z

M3 - Article

VL - 85

SP - 315

EP - 319

JO - Annals of Hematology

JF - Annals of Hematology

SN - 0939-5555

IS - 5

ER -